9p loss, which includes the tumor suppressor CDKN2A, was associated with upregulation of translation initiation, mTOR and MYC signaling, consistent with loss of CDKN2A and MYC activation previously reported in ccRCC progression (Bailey et al., 2017). This evidence concerns the gene CDKN2A and nonpapillary renal cell carcinoma.